Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Candell-Riera J, Ferreira-Gonzalez I, Marsal JR, Aguade-Bruix S, Cuberas-Borros G, Pujol P, Romero-Farina G, Nazarena-Pizzi M, de Leon G, Castell-Conesa J, Garcia-Dorado D. Usefulness of exercise test and myocardial perfusion-gated single photon emission computed tomography to improve the prediction of major events. Circ Cardiovasc Imaging. 2013 Jul;6(4):531-41. doi: 10.1161/CIRCIMAGING.112.000158
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Scrams DJ, McLeod LD. An expected response function approach to graphical differential item functioning. J Educ Meas. 2000 Jan 1;37(3):263-77.
Williams VSL, Rosa KR, McLeod L, Thissen D, Sanford EE. Projecting to the NAEP Scale: results from the North Carolina End‐of‐Grade Testing Program. J Educ Meas. 1998 Dec;35(4):277-96. doi: 10.1111/j.1745-3984.1998.tb00539.x
Williams VSL, Pommerich M, Thissen D. A comparison of developmental scales based on Thurstone methods and item response theory. J Educ Meas. 1998 Jun;35(2):93-107.